Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1654]

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone...

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )

War in Ukraine: Impacts on the Polish cancer care system and vaccination...

Prof Piotr Rutkowski - National Research Institute of Oncology, Warsaw, Poland

War in Ukraine: Impacts on the Polish cancer care system and vaccination challenges ( Prof Piotr Rutkowski - National Research Institute of Oncology, Warsaw, Poland )

Lymphoma Coalition: Challenges for Ukrainian haematological cancer patients

Prof Natacha Bolaños - Lymphoma Coalition, Madrid, Spain

Lymphoma Coalition: Challenges for Ukrainian haematological cancer patients ( Prof Natacha Bolaños - Lymphoma Coalition, Madrid, Spain )

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...

$Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )$

Recurrent non-invasive breast tumours may not always be related to the primary...

Dr Tanjina Kader - University of Melbourne, Melbourne, Australia

Recurrent non-invasive breast tumours may not always be related to the primary lesion ( Dr Tanjina Kader - University of Melbourne, Melbourne, Australia )

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer